Big Beat for Gilead on Rising Sovaldi Revenue

July 23 (Bloomberg) -- Gilead Sciences, maker of the hepatitis C pill Sovaldi, doubled its sales forecast for the year on better-than-estimated revenue from the blockbuster pill. Bloomberg’s Olivia Sterns reports on “Street Smart.” (Source: Bloomberg)
Investors Withdrew $2.7 Billion From Pimco in May
18:20 - Bloomberg’s Julie Hyman reports on breaking news on Pimco client redemptions. She speaks on “Bloomberg Markets.” (Source: Bloomberg)
  • Apple Is a Growth Stock in a Value Costume: Holland
  • Larry Fink: We Will Have Fed Action by September
  • Money Trail Got Too Close to Blatter: Jimmy Conrad